newsfilter
← Earnings
Earnings Releases·

Harrow — Third Quarter 2026 Earnings Summary

Harrow reported record third-quarter 2026 revenue of $99.3 million, representing a 39% year-over-year increase, driven by a 62% surge in branded product sales. The company achieved a GAAP net income of $9.8 million, which included a $5.0 million litigation settlement gain, while Adjusted EBITDA reached $21.2 million. Key product performance included VEVYE revenue of $39.7 million and TRIESENCE revenue of $10.7 million, alongside the October 1 acquisition of TYRVAYA. Harrow reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and updated its full-year Adjusted EBITDA outlook to more than $40 million.

Company
HARROW INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic